Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Description

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.

Conditions

Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.

Phase I/II Trial of Gabapentin Plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Condition
Head and Neck Cancer
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically proven cancer of the head and neck cancer
  • * Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
  • * Planned primary or adjuvant radiation or chemoradiation therapy
  • * Willing and able to provide informed consent
  • * ECOG PS 0-2
  • * Age ≥ 21 years
  • * English speaking
  • * Currently on gabapentin or ketamine
  • * Prior non-tolerance of gabapentin or ketamine
  • * Unable to administer ketamine intranasally due to anatomical restrictions
  • * History of seizure disorder
  • * History of schizophrenia
  • * History of increased intracranial pressure
  • * Glomerular filtration rate \<30 mL/min/1.73 m2

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Natalie Lockney,

Natalie Lockney, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt-Ingram Cancer Center

Study Record Dates

2026-12-31